Nicole Deglon

Lausanne, VD 1011, Switzerland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 77 publications

Selective striatal pathological changes in a novel human HTT exon 1 knock-in mouse model of Huntington's disease.

Selective striatal pathological changes in a novel human HTT exon 1 knock-in mouse model of Huntington's disease.

Journal: Experimental neurology
Published: April 16, 2025

Gene editing for Spinocerebellar ataxia type 3 taking advantage of the human ATXN3L paralog as replacement gene.

Gene editing for Spinocerebellar ataxia type 3 taking advantage of the human ATXN3L paralog as replacement gene.

Journal: Gene therapy
Published: February 13, 2025

Extracellular PHF-tau modulates astrocyte mitochondrial dynamics and mediates neuronal connectivity.

Extracellular PHF-tau modulates astrocyte mitochondrial dynamics and mediates neuronal connectivity.

Journal: Translational neurodegeneration
Published: April 25, 2024

Gene editing as a therapeutic strategy for spinocerebellar ataxia type-3.

Gene editing as a therapeutic strategy for spinocerebellar ataxia type-3.

Journal: Revue neurologique
Published: March 08, 2024

Mono- and Biallelic Inactivation of Huntingtin Gene in Patient-Specific Induced Pluripotent Stem Cells Reveal HTT Roles in Striatal Development and Neuronal Functions.

Mono- and Biallelic Inactivation of Huntingtin Gene in Patient-Specific Induced Pluripotent Stem Cells Reveal HTT Roles in Striatal Development and Neuronal Functions.

Journal: Journal of Huntington's disease
Published: March 01, 2024

Neuronal A2A receptor exacerbates synapse loss and memory deficits in APP/PS1 mice.

Neuronal A2A receptor exacerbates synapse loss and memory deficits in APP/PS1 mice.

Journal: Brain : a journal of neurology
Published: November 30, 2023

Limitations of Dual-Single Guide RNA CRISPR Strategies for the Treatment of Central Nervous System Genetic Disorders.

Limitations of Dual-Single Guide RNA CRISPR Strategies for the Treatment of Central Nervous System Genetic Disorders.

Journal: Human gene therapy
Published: September 02, 2023

Revisiting the outcome of adult wild-type Htt inactivation in the context of HTT-lowering strategies for Huntington's disease.

Revisiting the outcome of adult wild-type Htt inactivation in the context of HTT-lowering strategies for Huntington's disease.

Journal: Brain communications
Published: August 15, 2023

Tau Transfer via Extracellular Vesicles Disturbs the Astrocytic Mitochondrial System.

Tau Transfer via Extracellular Vesicles Disturbs the Astrocytic Mitochondrial System.

Journal: Cells
Published: February 15, 2023

Semi-automated workflows to quantify AAV transduction in various brain areas and predict gene editing outcome for neurological disorders.

Semi-automated workflows to quantify AAV transduction in various brain areas and predict gene editing outcome for neurological disorders.

Journal: Molecular therapy. Methods & clinical development
Published: January 03, 2023

Central Nervous System Gene Therapy: Present Developments and Emerging Trends Accelerating Industry-Academia Pathways.

Central Nervous System Gene Therapy: Present Developments and Emerging Trends Accelerating Industry-Academia Pathways.

Journal: Human gene therapy
Published: September 07, 2022

Tau promotes oxidative stress-associated cycling neurons in S phase as a pro-survival mechanism: Possible implication for Alzheimer's disease.

Tau promotes oxidative stress-associated cycling neurons in S phase as a pro-survival mechanism: Possible implication for Alzheimer's disease.

Journal: Progress in neurobiology
Published: May 23, 2022
Showing 1-12 of 77

Last Updated: 09/26/2026